Literature DB >> 18688218

Infections cast cloud over Novartis' MS therapy.

Ken Garber.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18688218     DOI： 10.1038/nbt0808-844

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Novartis eyes oral MS drug as potential blockbuster.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

2.  The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium.

Authors:  Carola T Murphy; Lindsay J Hall; Grainne Hurley; Aoife Quinlan; John MacSharry; Fergus Shanahan; Kenneth Nally; Silvia Melgar
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

3.  Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways.

Authors:  Young-Jin Seo; Curtis J Pritzl; Madhuvanthi Vijayan; Celeste R Blake; Mariah E McClain; Bumsuk Hahm
Journal:  J Immunol       Date:  2012-04-06       Impact factor: 5.422

4.  Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.

Authors:  Kevin B Walsh; David Marsolais; Megan J Welch; Hugh Rosen; Michael B A Oldstone
Journal:  Virology       Date:  2009-12-03       Impact factor: 3.616
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.